Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Core Insights - Tarsus Pharmaceuticals has initiated a Phase 2 clinical trial (Calliope) for TP-05 (lotilaner), an investigational oral therapy aimed at preventing Lyme disease by killing infected ticks before disease transmission occurs [1][2][3] Company Overview - Tarsus Pharmaceuticals focuses on innovative treatments across various therapeutic areas, including eye care, dermatology, and infectious disease prevention [7][8] - The company is advancing its pipeline with TP-05 for Lyme disease prevention and TP-04 for ocular rosacea, both currently in Phase 2 trials [8] Clinical Trial Details - The Calliope trial is a randomized, double-blind, placebo-controlled study involving approximately 700 healthy adults at risk for Lyme disease, with enrollment expected to complete during the 2026 tick season and topline results anticipated in the first half of 2027 [2][3] - The trial design is based on previous successful studies, including a Phase 2a proof-of-concept study that demonstrated over 90% tick mortality within 24 hours of TP-05 administration [4] Lyme Disease Context - Lyme disease is the most common vector-borne disease in the U.S., with over 35 million Americans at moderate to high risk and approximately 300,000 to 400,000 diagnosed annually [3][6] - There are currently no FDA-approved pharmacological prophylactic options for Lyme disease, highlighting the need for innovative preventive measures [3][6] Scientific and Public Health Implications - The shift from treating Lyme disease post-infection to a preventive approach could significantly impact public health, especially as climate change expands the geographic range of ticks [3][6] - New prophylactic options like TP-05 could address the increasing burden of tick-borne illnesses and reduce the risk of serious long-term complications associated with Lyme disease [3][6]